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Abstract.  Free  norepinephrine  and  epinephrine  were  measured  in two  consecutive 
12-hour  urine  collections  gathered  during  normal  activity  and  sleep  from  23 
panic-anxiety  patients  and  9 normal  subjects.  Mitral  value  prolapse  (MVP)  was 
found  in  7  of  20  patients  who  had  echocardiograms.  Mean  nighttime  nor- 
epinephrine  and  epinephrine  excretion  in panic-anxiety  patients  without  MVP  was 
significantly  higher  than  that  of control  subjects,  and  was  significantly  higher  than 
that  of  anxiety  patients  with  MVP.  In  the  daytime,  all  groups  had  higher 
catecholamine  (CA)  levels,  but  the  differences  between  the  groups  were  less 
pronounced.  Medication  significantly  relieved  symptoms  and  was  associated  with 
decreased  CA  levels.  Elevated  basal  CA  levels  may  characterize  the  subgroup  of 
panic-anxiety  patients  who  do  not  have  MVP. 
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Urinary  and  plasma  catecholamine  (CA)  elevations  in  normal  subjects  during  stress 
and  anxiety  have  been  well  documented  (Cannon,  19 15; Frankenhauser,  197 I ; Lader, 
1974;  Redmond,  1979;  Usdin  et  al.,  1980;  Ward  et  al.,  1983;  Nesse  et  al.,  in  press). 
There  have,  however,  been  relatively  few  studies  of CA  levels  in  patients  with  anxiety 
disorders  (Lader,  1978).  This  paucity  of studies  is surprising  in  view  of the  likelihood 
that  CAs  are  mediators  of  anxiety  symptoms,  and  the  possibility  that  elevated  CAs 
characterize  some  anxiety  disorders. 
Several  studies  report  correlations  between  CA  levels  and  anxiety  in  patients  with 
depression.  In  I3 drug-free  patients  with  depression,  elevated  plasma  CA  levels  were 
strongly  correlated  with  anxiety  ratings  (r=  0.69,~  <  O.Ol), but  were  weakly  correlated 
with  depression  ratings  (r  = 0.261)  (Wyatt  et  al.,  1971).  In  another  study  of  patients 
with  anxiety  and  depression,  red  blood  cell  (RBC)  catechol-O-methyltransferase 
(COMT)  levels  were  above  the  normal  range  only  in  the  patients  who  had  mainly 
anxiety  symptoms  (Shulman  et  al.,  1978). 
Randolph  M.  Nesse.  M.D.,  is Assistant  Professor,  OliverG.  Cameron.  M.D.,  Ph.D.,  is Assistant  Professor, 
and  George  C.  Curtis,  M.D.,  is  Professor,  Department  of  Psychiatry,  University  of  Michigan  Medical 
Center.  Andrew  J.  Buda,  M.D..  is Assistant  Professor,  and  Daisy  S.  McCann,  Ph.D.,  is Associate  Professor 
of  Biological  Chemistry,  Department  of  Internal  Medicine,  University  of  Michigan.  Marla  Huber-Smith. 
B.A.,  is  Research  Associate,  Wayne  County  General  Hospital.  Westland.  MI.  (Reprint  requests  to  Dr. 
R.M.  Nesse.  Dept.  of  Psychiatry,  University  of  Michigan  Medical  Center,  Box  56,  Ann  Arbor,  MI  48109, 
USA.) 
0165-1781/85/$03.30  0  1985  Elsevier  Science  Publishers  B.V.  (Biomedical  Division) 68 
Patients  with  generalized  anxiety  disorder  have  been  reported  to  have  plasma 
epinephrine  and  norepinephrine  levels  significantly  higher  than  controls,  but  their 
RBC  COMT  levels  were  only  slightly  above  those  of controls  (Mathew  et al.,  1980). 
The  same  group  of researchers  subsequently  failed  to confirm  elevations  of plasma  CA 
in  generalized  anxiety  patients,  and  suggested  that  the  earlier  work  might  have  been  in 
error  because  blood  samples  were  drawn  immediately  following  venipuncture 
(Mathew  et  al.,  1982).  Perhaps  patients  with  generalized  anxiety  disorder  have  a 
greater  CA  response  to  venipuncture  than  do  normals.  Increased  plasma  3-methoxy- 
4-hydroxyphenethyleneglycol  (MHPG)  has  been  significantly  correlated  with  anxiety 
ratings  in  normals  (Uhde  et al.,  1982)  and  in  phobic-anxious  patients  (Ko  et al.,  1983) 
but  comparisons  of plasma  MHPG  levels  in anxiety  disorder  patients  and  normals  are 
not  available.  There  is a trend  for  urinary  MHPG  excretion  to  be  higher  in  patients 
with  panic  attacks  when  compared  to  normal  controls  (Sheehan  et  al.,  1984). 
Patients  with  panic  disorder  have  been  reported  to  have  elevated  plasma  levels  of 
both  epinephrine  and  norepinephrine  (Nesse  et al.,  1984;  Cameron  et al.,  1984)  or  of 
epinephrine  only  (Appleby  et  al.,  1981).  Patients  who  had  a  panic  attack  during  a 
lactate  infusion  tended  to  have  higher  plasma  epinephrine  levels  than  other  patients, 
after  the  infusion  (Appleby  et al.,  198 1). In  that  study,  pre-infusion  epinephrine  levels 
were  reported  to  be equivalent  in  patients  who  did,  and  did  not,  develop  panic  attacks. 
A  more  recent  report  from  the  same  group  states  that  elevated  baseline  epinephrine 
was  “the  only  variable  that  distinguished  patients  who  went  on  to  panic  from  those 
who  did  not”  (Liebowitz  et al.,  1983).  Ballenger  et al.  (1984)  have  reported  significant 
elevations  of plasma  epinephrine  and  norepinephrine  in  36 patients  with  agoraphobia 
as  compared  to  9  normal  controls.  The  differences  were  more  pronounced  when 
subjects  were  lying  than  standing.  The  patients’  mean  level  of plasma  norepinephrine 
was  three  times  higher  than  that  of  the  normals  while  lying  down  (Ballenger  et  al., 
1984). 
Patients  with  panic  disorder  have  an  increased  prevalence  of mitral  valve  prolapse 
(MVP)  (Crowe  et al.,  1980).  People  with  MVP  have  anxiety-like  symptoms,  elevated 
plasma  CA  levels  (Boudoulas  et  al.,  1980;  DeCarvalho  et  al.,  1979;  Pasternac  et  al., 
1982; Gaffney  et al.,  1983)  and  elevated  urinary  CA  excretion  (Boudoulas  et al.,  1983). 
The  present  report  considers  the  hypothesis  that  the  elevated  CA  levels  reported  for 
panic  patients  are  an  indirect  result  of  the  increased  prevalence  of  MVP  in  panic 
patients.  Separate  measurement  of  daytime  and  nighttime  CA  excretion  rates  also 
allows  consideration  of  the  possibility  that  group  differences  in  CA  excretion  result 
from  different  daytime  activity  levels. 
Methods 
Subjects.  Twenty-three  patients  with  panic  disorder  or  agoraphobia  with  panic  attacks  were 
compared  to  nine  control  subjects  (see  Table  1). The  patients  had  requested  treatment  at  the 
University  of Michigan  Anxiety  Disorders  Clinic.  Diagnoses  were  made  according  to  DSM-III 
criteria  (American  Psychiatric  Association,  1980) after  a clinical  examination  by a psychiatrist 
experienced  in  diagnosing  anxiety  disorders.  The  controls  were  recruited  by  newspaper 
advertisements.  Their  psychiatric  examinations  revealed  no  anxiety  or  other  mental  disorder. 
All  subjects  were  physically  healthy  and  were  not  taking  medication.  All  but  two  subjects  had 
been  medication  free  for  a month  or  more.  One  patient  had  taken  4 mg of diazepam  and  4 mg  of 69 
trifluroperazine/  day,  and  another  had  taken  I5 mg  of  diazepam  and  40  mg  of  naldolol/  day, 
until  2 weeks  before  the  study. 
Table  1. Subjects 
Normal 
All  PD 
PD  w/MVP1 
PD  PD 
w/o  MVPl  w/o  ECHO1 
n  (total  = 32)  9  23  7  13  3 
Sex  (M/F)  7/2  5/18  l/6  3110  l/2 
Mean  age 
(years)  26.0  (5.21  32.0  (11.3)  35.6  (14.2)  29.1  (6.6)  3.60  (14.7) 
Mean  age  at 
onset  (years)  -  22.2  (10.9)  24.4  (14.2)  22.1  (9.5)  17.3  (10.21 
Mean  duration 
of  illness 
(years)  9.78  (9.68)  11.14  (9.72)  7.00  (7.15)  18.67  (16.26) 
Mean  weight 
(kg)  76.0  (12.7)  64.6  (11.0)  60.7  (8.4)  64.9  (12.6)  72.7  (12.4) 
Mean  height 
(cm)  176.3  (8.5)  165.9  (8.4)  163.6  (11.2)  166.3  (6.1)  169.3  (10.61 
PD =  panic  disorder;  PD  w/MVP  =  panic  disorder  with  mitral  valve  prolapse;  PD  w/o  MVP  =  panic  disorder 
without  mitral  valve  prolapse;  PD  w/o  ECHO  =  panic  disorder  without  echocardiogram;  standard  deviations 
given  in  parentheses. 
1. Subgroups  of  the  All  PD  group. 
Urine  Collections.  Subjects  received  verbal  and  written  instructions  regarding  the  urine 
collection  technique  and  schedule.  They  were  instructed  to  follow  their  usual  diet  but  to  avoid 
all  strenuous  exercise,  medication,  and  caffeinated  and  alcoholic  beverages  during  the  urine 
collection.  Two  consecutive  12-hour  samples  (7 a.m.-7  p.m.;  7 p.m.-7  a.m.)  were  collected  in jugs 
containing  10 ml of 5% acetic  acid.  Within  24 hours  of collection,  urine  samples  were  brought  to 
the  laboratory,  where  total  volume  was  recorded  and  samples  were  labeled  and  frozen  at -20°C. 
After  3-14  months  of  treatment  with  imipramine,  alprazolam,  or  a  P-blocker,  10  patients 
collected  urine  a second  time  according  to  the  same  protocol.  Urine  samples  were  excluded  if 
total  volume  was  less  than  300  ml/  12 hours  or  if creatinine  content  was  less  than  0.3  mg/  12 
hours. 
Assay.  Epinephrine  and  norepinephrine  were  assayed  by  our  modification  of  a single  isotope 
derivative  radioenzymatic  technique  (McCann  and  Huber-Smith,  1984).  This  assay  has  an 
intra-assay  coefficient  of variation  of 3.92%,  and  an  inter-assay  coefficient  of variation  of  10.7%. 
Mitral  Valve  Prolapse  Evaluation.  Twenty  of  the  patients  and  three  of  the  controls  had  a 
phonocardiogram,  auscultation  by  a  cardiologist,  and  two-dimensional  and  M-mode 
echocardiograms,  to  determine  if  MVP  was  present.  The  MVP  evaluations  were  assessed 
independently  by  three  cardiologists  who  were  blind  to  the  clinical  diagnosis,  and  MVP  was 
considered  present  only  if at  least  two  of  the  cardiologists  agreed  on  that  diagnosis,  based  on 
M-mode  or  two-dimensional  echocardiographic  data  that  were  interpreted  using  standard 
criteria.  On  M-mode  echocardiography,  MVP  was  considered  present  if mid-systolic  buckling 
or  systolic  hammocking  of  2 mm  posterior  to  the  C-D  point  was  observed  (Markiewicz  et  al., 
1976).  On  two-dimensional  echocardiogram,  MVP  was  defined  by  specific  criteria  for  the 
parasternal  long-axis  view  (Gilbert  et  al.,  1976)  and  for  the  apical  four-chamber  view 
(Morganroth  et  al.,  1980). 70 
SCL-SO.  Subjects  completed  the  Symptom  Checklist  90-R  (SCL-90)  at  the  initial  evaluation 
and  again  at the  second  urine  collection. 
Data  Analysis.  Epinephrine  and  norepinephrine  data  were  analyzed  separately  at each  time  of 
day.  Analyses  of variance  (ANOVAs)  with  planned  contrasts  were  used  to compare  the  groups. 
Results 
Seven  of  the  20  patients  who  received  echocardiograms  (35%)  had  MVP.  Of  three 
control  subjects  who  had  echocardiograms,  none  had  MVP.  Estimates  of  the 
prevalence  of MVP  using  the  same  criteria  for  women  in the  general  population  are  in 
the  range  of  6%  to  21%  (Markiewicz  et  al.,  1976;  Rosenberg  et  al.,  1983). 
Patients  excreted  more  of each  CA  during  daytime  and  at  night,  but  the  difference 
was  significant  only  for  nighttime  norepinephrine  @ <0.036).  The  13 patients  who  did 
not  have  MVP  excreted  substantially  more  CA  than  either  patients  with  MVP  or 
normal  controls  (see  Fig.  1 and  Table  2). These  differences  were  much  more  prominent 
Fig.  1. Urinary  free  norepinephrine  and  epinephrine 
DAYTIME  NOREPINEPHRINE  tpg/12  h)  NIGHTTIME  NOREPINEPHRINE  (gg/12  hl 
DAYTIME  EPINEPHRINE  (/.ig/lZ  hl  NIGHTTIME  EPINEPHRINE  1~9112  h) 
Significance  levels  refer  to  comparisons  with  normals,  unless  otherwise  indicated. 71 
Table  2.  Mean  (SD)  urinary  norepinephrine  (pg/12  hours) 
n  Day 
All  PD  22  21.48  (11.43) 
PD  WIMVP  7  19.28  (11.14) 
PD  w/o  MVP  12  22.35  (12.901 
All  normals  9  13.84  (6.19) 
Night 
18.38  (7.86) 
10.94  (4.22) 
19.48  (8.49) 
8.96  (5.12) 
All  PD  vs.  all  normals  F =  3.12,  p  <  0.088 
PD  w/MVP  vs.  normals  F =  1.05 
PD  w/o  MVP  vs.  normals  F =  3.36,  p  <  0.078 
PD  w/MVP  vs.  PD  w/o  MVP  F =  0.38 
F = 4.89,  p < 0.036 
F =  0.33 
F =  12.27,  p  <  0.002 
F=7.43,,-1<0.011 
Mean  (SD)  urinary  epinephrine  (pg/12  hours) 
n  Day 
All  PD  22  8.54  (5.32) 
PD  w/MVP  7  7.43  (5.10) 
PD  w/o  MVP  12  9.85  (5.80) 
All  normals  9  7.09  (2.801 
Night 
6.52  (3.81  ) 
4.47  (3.00) 
7.88  (4.03) 
4.14  (2.35) 
All  PD  vs.  all  normals 
PD  w/MVP  vs.  normals 
PD  w/o  MVP  vs.  normals 
PD  w/MVP  vs.  PD  w/o  MVP 
F=O.lO 
F =  0.02 
F =  1.75 
F=  1.16 
F =  1.53 
F =  0.03 
F =  6.20,  p  <  0.019 
F =  4.75,  P <  0.038 
See  note to Table  1 for abbreviations 
at  night.  Patients  without  MVP  had  nighttime  epinephrine  excretion  significantly 
greaterthan  bothcontrols(F=6.19,p<O.O19)and  patients  with  MVP(F=4.75,p< 
0.038).  Patients  without  MVP  had  nighttime  norepinephrine  excretion  that  was 
significantly  higher  than  both  controls  (F=  12.27,~  <  0.002) and  patients  with  MVP 
(F=  7.43,~  <  0.011).  In  the  daytime,  the  differences  between  patients  with  and  without 
MVP  were  minimal,  while  the  differences  persisted  between  controls  and  patients 
without  MVP. 
Nonparametric  presentation  of these  data  shows  the  consistency  of the  differences. 
For  nighttime  epinephrine,  18 of 23 patients  (78%)  had  values  greater  than  the  median 
for  controls,  and  11 (48%)  had  values  greater  than  the  maximum  for  controls.  Eleven 
of the  13 patients  without  MVP  (85%)  had  values  greater  than  the  median  for  patients 
with  MVP.  For  nighttime  norepinephrine,  21 of 23 patients  (91%)  had  levels  greater 
than  the  median  for  controls,  and  8 of 23 (35%)  had  levels  greater  than  the  maximum 
for  controls.  Ten  of  the  13 patients  without  MVP  (77%)  had  levels  greater  than  the 
median  for  patients  with  MVP. 
A  two-way  ANOVA  was  performed  to  consider  the  effect  of  time  of  day  and  its 
possible  interaction  with  diagnosis.  Norepinephrine  excretion  and  epinephrine 
excretion  were  both  significantly  lower  at  night  (F  = 10.04,  p  <  0.004  and  F  q 8.38, 
p <  0.008,  respectively),  but  there  were  no  significant  interactions  between  time  of day 
and  diagnosis. 72 
After  3-14  months  of  medication,  SCL-90  subscale  scores  had  significantly 
decreased  (see  Table  3).  Urinary  free  epinephrine  and  norepinephrine  decreased  after 
treatment,  but  the  difference  approached  statistical  significance  only  for  nighttime 
norepinephrine  excretion  (F  = 2.24,  p  <  0.056).  CA  levels  decreased  more  during 
treatment  for  those  patients  without  MVP  than  for  those  with  MVP,  but  the  small 
number  of  subjects  precludes  more  formal  comparison. 
The  data  were  also  analyzed  with  a two-way  ANOVA  (diagnosis  by  sex)  with  three 
covariates  (age,  weight,  and  height)  and  planned  contrasts  in  order  to  consider  the 
possibility  that  the  results  might  be  accounted  for  by  group  differences  in  sex,  age, 
weight,  or  height.  The  effects  of  sex,  of  the  sex  by  diagnosis  interaction,  and  of  the 
covariates  were  all  insignificant  @ <  0. lo),  and  significant  differences  found  in  the 
main  analysis  remained  significant  in  this  analysis.  Although  the  difference  is  not 
statistically  significant,  it is of interest  that  patients  without  MVP,  when  compared  to 
those  with  MVP,  had  an  earlier  age  of onset  (22.1  vs. 24.4 years)  and  a shorter  duration 
of  illness  before  seeking  treatment  (7.00  vs.  11.14 years),  possibly  reflecting  greater 
severity  of illness.  At  the  time  of evaluation,  however,  patients  with  MVP  had  higher 
SCL-90  anxiety  scores  than  patients  without  MVP  (3.1  vs.  2.6;  t  q  1.36, p  <  0.19). 
Table  3.  Mean  values:  Pretreatment  vs. during  treatment 
During 
Pretreatment  treatment  t  D 
Daytime  epinephrine  in  =  10)  8.05 
Nighttime  epinephrine  in  =  9)  5.52 
Daytime  norepinephrine  (n  =  10)  21.36 
Nighttime  norepinephrine  (n  =  9)  15.54 
SCL  anxiety  (n  =  8)  3.10 
SCL  somatic  in  =  8)  2.10 
SCL  phobic  (n  =  8)  2.60 
SCL  obsessive-compulsive  (n  =  8)  1.75 
SCL  deoression  (n  =  8)  2.35 
7.24  1.23  NS 
4.40  1.50  NS 
20.54  0.12  NS 
10.59  2.24  0.056 
1.52  3.20  0.015 
1.37  3.15  0.016 
1.53  2.76  0.028 
1.02  2.66  0.033 
1.27  2.97  0.021 
Discussion 
This  study  supports  the  increased  prevalence  of MVP  reported  for  patients  with  panic 
anxiety,  and  it  confirms  prior  reports  of  elevated  CA  levels  in  patients  with  panic 
disorder.  Panic  patients  with  MVP  have  free  CA  excretion  rates  generally  similar  to 
those  of  controls,  while  panic  patients  without  MVP  have  CA  excretion  rates 
significantly  greater  than  either  normals  or  panic  patients  with  MVP.  These 
unexpected  group  differences  .were  more  pronounced  for  norepinephrine  than 
epinephrine.  The  present  findings  differ  from  some  plasma  studies  in  which 
epinephrine  differences  predominated,  but  are  consistent  with  the  other  plasma 
studies  (Ballenger  et  al.,  1984).  Urine  studies  of  CA  metabolites  would  augment  the 
free  CA  results  reported  here. 
These  results  differ  from  prior  reports  of elevated  plasma  CAs  in subjects  who  have 
MVP.  The  discrepancy  could  result  from  differences  between  urinary  and  plasma 73 
CAs,  or from  differences  between  MVP  subjects  who  do  and  do  not  have  panic.  It may 
be,  however,  that  the  failure  to  find  a  significant  difference  between  normals  and 
anxiety  patients  with  MVP  is a type  I1 error  resulting  from  small  sample  size.  For  both 
CAs,  the  differences  between  groups  were  larger  at night.  This  suggests  that  the  groups 
differ  in  basal  CA  secretion  rates  and  that  daytime  activity  differences  between  the 
groups  do  not  account  for  the  findings.  Data  are  not  available  to  consider  the 
possibility  that  the  groups  differed  in  activity  levels  or  posture  at  night. 
Patients  in  this  study  demonstrated  substantial  benefit  from  treatment  with 
alprazolam  or  imipramine,  but  group  sizes  were  too  small  to  allow  correlation  of 
treatment  response  with  pretreatment  findings.  The  finding  of  decreased  CA  levels 
during  prolonged  treatment  is at  variance  with  some  reports  (Ballenger  et al.,  1984), 
but  is  consistent  with  the  observation  that  imipramine  treatment  causes  a  rise  in 
plasma  CAs  that  peaks  at  about  14 weeks  of  treatment  and  then  declines  toward 
baseline  (Cameron  et  al.,  1984).  A  study  of  CA  levels  in  successfully  treated 
panic-anxiety  patients  who  are  off medication  would  help  to differentiate  drug  effects 
from  changes  associated  with  symptomatic  improvement. 
These  results  contradict  the  hypothesis  that  elevated  CA  levels  in  panic-anxiety 
patients  are  accounted  for  by  the  subgroup  of  patients  with  MVP,  and  suggest, 
instead,  that  the  observed  CA  elevations  result  mainly  from  the  subgroup  of  panic 
patients  without  MVP.  If this  difference  in  CA  excretion  between  patients  with  MVP 
and  without  MVP  is confirmed,  it  might  provide  an  important  clue  to  the  existence 
and  etiologies  of two  distinct  subgroups  of patients  with  panic.  The  number  of subjects 
in  this  study  is small,  so no  firm  conclusion  is yet justified,  but  studies  of patients  with 
panic  attacks  will  need  to  consider  the  possibility  that  subgroups  with  and  without 
MVP  may  differ  on  other  variables,  in  addition  to  their  rate  of  CA  excretion. 
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